Bocidelpar

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 00:49, April 25, 2022 by Notjusttired (talk | contribs) (create)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Bocidelpar or ASP0367 or MA-0211 is an experimental drug that may improve mitochondria and endothelial function.[1] Bocidelpar is undergoing clinical trials under the name ASP0367 for Duchenne Muscular Dystrophy, ME/CFS and a number of other diseases mitochondria involving mitochondria dysfunction.[1][2]

Theory[edit | edit source]

Evidence[edit | edit source]

The first clinical trial for ME/CFS is trial NCT04855201, which has not yet published any results. The trial involves 40 adults aged between 18 and 60, and is randomized clinical trial with quadruple blinding.[2]

Clinicians[edit | edit source]

David Systrom is helping conduct the current clinical trial of bocidelpar at Brigham and Women's Hospital, Boston, United States.[3]

Risks and safety[edit | edit source]

Unknown.

Costs and availability[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 https://www.parentprojectmd.org/drug-development-pipeline/ma-0211-mtb-1/
  2. ↑ 2.0 2.1 https://clinicaltrials.gov/ct2/show/NCT04855201?term=ASP0367&draw=2&rank=5
  3. ↑ https://www.healthrising.org/blog/2022/04/23/mitochondrial-chronic-fatigue-syndrome/

blinded trial A clinical trial is blinded if either the participants or the researchers don't know which treatment group they are allocated to until after the results are interpreted. (Learn more: www.nottingham.ac.uk)

Retrieved from "https://me-pedia.org/w/index.php?title=Bocidelpar&oldid=105386"